NBCD’s Post

This was quite a track record of performance for Cybin over the past year: - Positive phase 2 safety and efficacy readout for CYB003 as an adjunctive treatment for MDD - Around 75% of MDD patients in remission after just two doses - sustained for at least 4 months - Breakthrough Therapy Designation awarded to CYB003 by FDA - Successful recruitment of 30 sites for an upcoming phase 3 study of CYB003 in MDD this summer - Closing and integration of the Small Pharma team, along with programs and IP - Acceleration of CYB004 IM formulation aimed at delivering a 90 minute experience - Initiation of a phase 2 study of CYB004 in GAD with top line results expected around year end 2024

If you're at Biotechnology Innovation Organization meeting this year, go find Mike Burfield and RDI Partners to learn about the Australian R&D tax incentives they can help you leverage!

Meet Dr Steven Dodd at the BEBPA 2024 European Bioassay Conference! We are thrilled to announce that our Head of Sales, Steven Dodd, will be attending the BEBPA 2024 European Bioassay Conference this week in Prague! Steven is excited to connect with our existing customers, meet new potential partners, and explore opportunities to collaborate on innovative life science analysis software solutions. This event is a great platform to discuss how our software can automate your bioassay workflows and drive greater efficiency in the life sciences. Whether you're a current customer or someone new to our solutions, Steven would love to schedule a time to chat. Don’t miss the chance to engage in insightful conversations about the future of bioassays and life sciences software development in general! If you're attending, feel free to reach out to schedule a meeting with Steven! Like, share, and comment if you're attending or want to set up a time to meet with us in Prague. #bebpa2024 #bioassay #lifesciencesoftware #stevendodd #softwaredevelopment #biotech #biotechsoftware #pragueevents #businessdevelopment #biopharma #sales #biotechnology #pharmaindustry #lifesciences

In this interview, hear from Aaron Moulin and Johanna Howson from Purolite, An Ecolab Company at #BIO2024 as they introduce the DurA Cycle A50, a protein A chromatography resin for large-scale purification processes. 👀 Read more about the DurA Cycle here: https://lnkd.in/ewZ9rn9t 📽 And watch the full interview, below 👇 https://lnkd.in/egCHQbmK #BIO24 #Proteins #mAbs

🥸 FDA-cleared SeptiCyte test, a new diagnostic tool that can quickly identify Sepsis within 1 hour, helping doctors treat it faster and avoid unnecessary antibiotics or even death 💜. DM me for details/meeting. #sepsis #mortality #patientcare #patientsafety #malpractice #infection #criticalcare #emergencydepartment #ICU #antibioticstewardship

If you are at #bioeuropespring be sure to drop by One Nucleus booth 102B to discuss how CPI can help accelerate your biological therapeutics to market. #BioEuropeSpring #LetsInnovateTogether #CPI #Innovation #Pharma #Upstream #Downstream #Analytical #Formulation #ProcessDevelopment #Microbial #Mammalian #ViralVectors #mRNA #Vaccines #Microbiome #Phage

📡 #BioVersys delivers more impressive news in 2024: announcing last patient, last visit in the Phase 2 clinical trial with its lead asset BV100 and provides a business update. 🎯 Following hot on the heals of the, -  strategic investment by #GIBF in September and launch of BV100 clinical program in China, and -    completion of Phase 2a for alpibectir, BioVersys’ anti-TB molecule that showed PoC in TB patients earlier this year;   🚀 BioVersys is delighted that BV100 has also successfully completed its Phase 2 trial in ventilator associated bacterial pneumonia patients with strong first signs of efficacy. 🚑🛌   🌟 BV100 has the potential to address a large worldwide unmet medical need of patients with Carbapenem-Resistant Acinetobacter baumannii (CRAB) infections, that have limited treatment options. 🌍 🏥 Read the full press release here: https://lnkd.in/d5mS89Yt #SavingLivesinResistantTimes #HealthcareInnovation #antibiotics #AMR #investment #biotech #Europe #China 

Not all #hepatocytes are suited for all assays. Different hepatocyte formats have inherent characteristics that make them more suited for certain assays over others. Read our new blog post outlining the major differences between hepatocyte products and how they might be most useful in your research: https://lnkd.in/gEQUJDDe #ADME #DMPK #DrugMetabolism #DrugInteractions

Facing challenges with safe, compliant sample storage? Let BioKryo handle it! At BioKryo, we specialize in high-standard sample management services.   With full #traceability, customizable #cryopreservation temperatures, and both short- and long-term storage options, we ensure that every #sample is protected, from collection to #storage 🧪   Our European network of #biobanks makes samples accessible from multiple locations while securing your entire cold chain. Here’s how our approach can streamline your processes:  🌎Outsource the complexity:  BioKryo handles logistical challenges, equipment upkeep, and regulatory compliance, freeing up your team’s resources  🔎Traceability: You benefit from a robust monitoring system that provides full transparency and sample safety  🧊Cold chain assurance at every step: With consistent storage conditions, your samples remain protected at all stages, from 4°C to -196°C   Avoid the heavy investment in cryogenic facilities and complex accreditations—BioKryo provides centralized, flexible storage options and dedicated logistics on demand 👉Ready to protect your samples? Reach out to explore our customizable sample management solutions!  (link below) AFSSI Sciences de la Vie MabDesign Network POLEPHARMA France BioLead France Biotech Medicen Paris Region #biobanking #samplesafety #riskmanagement #cryopreservation #quality #flexibility #safeguarding